Qilu Network Lightning News On January 18, the 25th National Member Congress of the Chinese Pharmaceutical Association was held in Beijing in the form of a combination of online and offline. The meeting elected the 25th Board of Directors, and Li Yan, President of Qilu Pharmaceutical Group, was elected as the Vice Chairman of the 25th Council.
The Chinese Pharmaceutical Association is one of the earliest established academic groups in modern China, always standing at the forefront of promoting the development of pharmaceutical science and technology in mainland China, with the purpose of promoting the development of pharmaceutical science and technology, and is an important force in promoting the healthy development of pharmaceutical science and technology and the national pharmaceutical industry.
As the leader of Qilu Pharmaceutical, Li Yan has made suggestions for the development of the pharmaceutical industry over the years, speaking on behalf of the industry, and taking meeting the people's demand for higher level medical care as an unswerving goal. Li Yan led Qilu Pharmaceutical Group to always "resonate with the same frequency" with the state, "heart to heart" with patients, adhere to the innovation-driven strategy and internationalization strategy, and achieve sustained high-speed and high-quality development. In 2021, Qilu Pharmaceutical achieved remarkable results, with 23 new products approved for listing, including two class 2.2 improved new drugs; 1 new drug Iruk tablets marketing applications accepted by CDE; and 9 class 1 new drugs approved clinically.
Qilu Pharmaceutical continues to forge its core competitiveness, and is committed to the research and development of drugs for the treatment of common diseases, multiple diseases and other diseases that seriously endanger human health. 49 drugs are the first or exclusively listed in China, 7 have won the second prize of the National Science and Technology Progress Award, and have been ranked among the top 100 in China's pharmaceutical industry for many consecutive years.
Qilu Pharmaceutical is willing to work with the Chinese Pharmaceutical Association and the industry to solve the problem of drug use for the Chinese people, solve the problem of clinical urgent needs, and contribute more to promoting the development of China's medical science and technology, building a healthy China and building a human health community.
Lightning News reporter Zhou Yingchun reported